C-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal Degeneration (FTD) diagnosis yesterday. Also known as frontotemporal degeneration, the Association for Frontotemporal Degeneration (AFTD) defines FTD as a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the brain. This means that brain cells die in specific parts of the brain, causing multiple symptoms to emerge over time, as the disease progresses.
“FTD is a life-altering rare neurodegenerative disorder that affects not only patients, but their families and loved ones. At C-Path, we are committed to accelerating new treatments that will make a meaningful impact on the lives of those affected by these disorders,” said C-Path Vice President Rare and Orphan Disease Programs Collin Hovinga, Pharm.D.
The work being done at C-Path within its various consortia and programs, including the Critical Path for Rare Neurodegenerative Diseases (CP-RND) and its Rare Disease Cures Accelerator-Data Analytics Platform (RDCA-DAP), brings together multiple experts to accelerate and advance our understanding of disease pathology, treatment options, diagnostics and drug development.